Eli Lilly and Company (NYSE:LLY) announced on November 12, 2026, that it has broken ground on a $3.5 billion injectable medicine manufacturing facility in Fogelsville, Pennsylvania, as part of the company's broader $50 billion U.S. production expansion.

Key Highlights

  • $3.5 billion investment: The Lehigh Valley facility in Fogelsville, Pennsylvania, is part of Lilly's $50 billion push to expand medicine production in the U.S.
  • Retatrutide manufacturing: The site will add capacity for retatrutide, described as "a first-in-class investigational GIP, GLP-1 and glucagon triple hormone receptor agonist."
  • Job creation: The facility is expected to create 850 high-wage jobs and approximately 2,000 construction jobs.
  • Operational target: The site is expected to be operational by 2031.
  • LEED Gold target: The facility is targeting Leadership in Energy and Environmental Design (LEED) Gold certification.
  • Community commitment: Lilly will provide up to $1 million over five years to the Upper Macungie Township Community Fund for a nutrition and healthy living initiative.
  • 10 U.S. sites since 2020: The Lehigh Valley site is one of 10 new U.S. manufacturing sites Lilly has announced since 2020, with four dedicated to injectable medicines and devices.

Lilly's Lehigh Valley Groundbreaking: Facility Details and Strategic Context

According to the filing, Eli Lilly and Company broke ground on a $3.5 billion manufacturing facility in Fogelsville, Pennsylvania's Lehigh Valley on November 12, 2026. The company disclosed that the site is one of four among its 10 newly announced U.S. locations dedicated to injectable medicines and devices, with the others being in Research Triangle Park and Concord, North Carolina, and Kenosha, Wisconsin. The facility forms part of what the company described as a "$50 billion push to expand medicine production in the U.S."

The filing states that the Lehigh Valley site will manufacture injectable medicines, including retatrutide, which Lilly characterizes as an investigational molecule currently being studied in several Phase 3 clinical trials. Those trials are evaluating retatrutide's potential in obesity, overweight with weight-related medical problems, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular outcomes, and metabolic dysfunction-associated steatotic liver disease. The filing notes that "retatrutide is an investigational molecule that cannot be legally sold or marketed for human use." The filing's cautionary language states there is "no guarantee" that retatrutide will receive regulatory approval or prove safe and effective.

The company disclosed that the facility will employ machine learning, AI, digitally integrated systems, and advanced data analytics. Edgardo Hernandez, Executive Vice President and President of Lilly Manufacturing Operations, stated in the filing that each production run goes through "more than 5,000 documented steps" and each unit is "imaged and inspected more than 70 times to check for defects." Lilly is currently hiring for the site, which is expected to be fully operational by 2031.

What Was Disclosed

Lilly disclosed the groundbreaking of a $3.5 billion injectable medicine manufacturing facility in Fogelsville, Pennsylvania, expected to be operational by 2031, create 850 high-wage jobs and 2,000 construction jobs, and manufacture retatrutide among other medicines.